The Latest Breaking News from EMBC

Driven by an increasingly prominent aging population and technological breakthroughs, the prospects of the medical devices industry are surging. So, should investors looking to capitalize on the industry’s growth prospects add Embecta (EMBC) to their portfolio? Read more….

The healthcare industry is set for growth due to evolving healthcare demands and the rapid evolution of medical technologies. Hence, investors might consider investing in healthcare stocks, Becton, Dickinson and Co. (BDX), Zimmer Biomet Holdings (ZBH), and Embecta (EMBC). Read more….

Despite being a market leader in insulin pen needles and syringes, Embecta Corp (NASDAQ: EMBC) may face challenges ahead, since the markets are already mature and the company has not diversified, according to BofA Securities.

Becton Dickinson and Co's (NYSE:BDX) pure-play diabetes spin-off Embecta Corp (NASDAQ:EMBC) has reported Q2 sales of $274.5 million, down 3.4% on a reported basis, down 1.3% on a constant currency basis. Of the decrease, $6.0 million was attributable to unfavorable effects from foreign currency translation.  Volume unfavorably impacted revenues by approximately $3.7 million, primarily…